{"canonical":"https://abierto.us/vendors/biolink-life-sciences-inc-gusqrgkrz4c9","key":"GUSQRGKRZ4C9","name":"BIOLINK LIFE SCIENCES, INC.","uei":"GUSQRGKRZ4C9","city":"CARY","state":"NC","awards":1,"obligated":"-542764.00","notices_won":0,"top_agency_name":"Office of Assistant Secretary for Preparedness and Response","top_naics":"541715","cage":"1WR74","parent_name":"BIOLINK LIFE SCIENCES, INC.","also_known_as":[],"country":"USA","actions":2,"first_action":"2024-05-14","last_action":"2025-07-16","breakdowns":{"naics":[{"key":"541715","name":null,"awards":1,"obligated":"-542764.00"}],"places":[{"key":"NC","name":null,"awards":1,"obligated":"-542764.00"}],"agencies":[{"key":"7505","name":"Office of Assistant Secretary for Preparedness and Response","awards":1,"obligated":"-542764.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":1,"obligated":"-542764.00"}],"competition":[{"key":"COMPETED UNDER SAP","name":null,"awards":1,"obligated":"-542764.00"}],"product_service_codes":[{"key":"AN15","name":null,"awards":1,"obligated":"-542764.00"}]},"awards_list":[{"award_key":"CONT_AWD_75A50122C00068_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50122C00068_7505_-NONE-_-NONE-/","piid":"75A50122C00068","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"GUSQRGKRZ4C9","recipient_name":"BIOLINK LIFE SCIENCES, INC.","recipient_uei":"GUSQRGKRZ4C9","recipient_cage":"1WR74","recipient_city":"CARY","recipient_state":"NC","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-05-14","last_action_date":"2025-07-16","actions":2,"obligated":"-542764.00","current_total_value":"207236.00","potential_total_value":"207236.00","naics":"541715","psc":"AN15","extent_competed":"COMPETED UNDER SAP","set_aside":"NO SET ASIDE USED.","offers_received":100,"description":"BIOLINK - TO INVESTIGATE AND DETERMINE IF TREATMENT WITH RAMATROBAN, ADMINISTERED FOR 28 DAYS TO HOSPITALIZED, NON-ICU PATIENTS WITH COVID-19 PNEUMONIA, REDUCES THE RISK OF SUBSEQUENT DEVELOPMENT OF PASC OVER THE ENSUING 11 MONTHS. PROVIDED DATA","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":1,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}